BethEmmieSafirsteinMD

Neurology • Hallandale Beach, FL

Principal Investigator/Medical Director

Join to view full profile

Dr. Safirstein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Safirstein's full profile

Already have an account?

Office
911 E Hallandale Beach Blvd
Hallandale Beach, FL 33009
Phone+1 954-455-5757

Summary

Dr. Beth Safirstein is a Board Certified Neurologist in Hallandale Beach, FL. She received her medical degree from Indiana University School of Medicine, trained at University of Miami/Jackson Memorial Hospital and has been in practice 24 years. She is experienced in sleep medicine, Alzheimer's Disease, Parkinson's Disease, non-alcoholic fatty liver disease, Schizophrenia, Bipolar Disorder, Major Depressive Disorder, Vaccine clinical trials, Pharmacokinetic trials, Pharmacodynamic trials, and obesity and obesity-related disorders. She has more than 30 publications and over 500 citings.

Education & Training

Indiana University School of MedicineClass of 1996
Indiana UniversityB.A., 1988 - 1992

Certifications & Licensure

FL State Medical License 1999 - 2025
American Board of Psychiatry and Neurology Neurology
National Board of Physicians and Surgeons Neurology

Awards, Honors, & Recognition

Conference Educational Grant American Academy of Neurology, 2000
Strathmore's WHO's WHO 2000
George Paff Teaching Award University of Miami School of Medicine, 1998
Educational Grant Wal-Mart Foundation, 1988
Join now to see all

Clinical Trials

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease Start of enrollment: 2008 Oct 01
Completed
Phase 1
Study of Sleep-maintenance Activity of 3 Doses of SKP-1041 Start of enrollment: 2010 May 01
Completed
Phase 2
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext Start of enrollment: 2013 Mar 01
Completed
Phase 2, Phase 3
Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease Start of enrollment: 2014 Jun 01
Completed
Phase 1
Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease Start of enrollment: 2018 Dec 13
Completed
Phase 2, Phase 3
Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease Start of enrollment: 2020 Aug 04
Completed
Phase 1
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations Start of enrollment: 2020 Oct 27
Completed
Phase 3
Roles: Contact
Evaluation of the Biodistribution and Safety of 99mTC-Etarfolatide (EC20) in Normal Volunteers Start of enrollment: 2013 Apr 01
Completed
Phase 1
A Study to Assess Single and Multiple Doses of IkT-148009 in Healthy Elderly Participants and Parkinson's Patients Start of enrollment: 2021 Feb 16
Completed
Phase 1
A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD Start of enrollment: 2021 Jun 21
Completed
Phase 1
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine Start of enrollment: 2021 Jun 30
Completed
Phase 3
Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease Start of enrollment: 2021 Nov 03
Active, not recruiting
Phase 3
Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants Start of enrollment: 2022 Mar 24
Completed
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

192 citations
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinica...
Joseph Jankovic, Ira J. Goodman, Beth Safirstein, Tonya K. Marmon, Dale Schenk
JAMA Neurology. 2018-10-01
221 citations
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
Lisa M Dunkle, Karen L Kotloff, Cynthia L Gay, Germán Áñez, Jeffrey M Adelglass
The New England Journal of Medicine. 2022-02-10
125 citations
A single ascending dose study of bapineuzumab in patients with Alzheimer disease.
Ronald Black, Reisa A. Sperling, Beth Safirstein, Ruth N. Motter, Allan Pallay
Alzheimer Disease and Associated Disorders. 2010-04-01

Journal Articles

Successful treatment of hemichorea with olanzapine
Beth Safirstein, MD, Lisa Shulman, MD, and William Weiner, MD, Movement Disorders, 1/23/2001

Abstracts/Posters

Rivastigmine and Concomitant Memantine in Alzheimer's Disease: Safety and Tolerability
Beth Safirstein, Xiangyi Meng, Jason T. Olin, CNS Spectr, 1/1/2010
Lamotrigine for Treatment of Pain Associated with Diabetic Neuropathy: Results of two randomized, double-blind, placebo-controlled studies
Vinik Al et al, Pain, 1/1/2006
AX-PC-003 Phenserine in patients with Alzheimer's Disease
Safirstein BE, Neurology
Stroke and the Presidency
Safirstein BE, Stroke
Olanzepine and Hemiballism
Safirstein BE, Neurology
Long-term Memantine treatment in Moderate to Severe Alzheimer's Disease: 28 week open label extension of two randomized controlled trials
Safirstein BE
Alzheimer's Disease: Minority Health Disparity and Clinical Drug Trial
Safirstein BE
Efficacy of Lamotrigine in painful diabetic neuropathy: results from two large randomized double-blind trials
Safirstein BE
Safety, Tolerability and Pharmacokinetics of Multiple Doses of Lecozotan in Patients with Alzheimer's Disease
R.S. Black, E. Murray, S. Raje, Y. Zhao, P. Lucas, K. Wilks, B. Safirstein, D. Crimmins, M. Woodward, 10th International Conference on Alzheimer's Disease and Related Disorders, Madrid, Spain, 1/15/2006
Join now to see all